洞察市场格局
解锁药品研发情报

免费客服电话

18983288589
试用企业版

【ChiCTR2000040265】Impact of COVID-19 pandemic on Hepatobiliary and Pancreatic surgical services

基本信息
登记号

ChiCTR2000040265

试验状态

结束

药物名称

/

药物类型

/

规范名称

/

首次公示信息日的期

2020-11-26

临床申请受理号

/

靶点

/

适应症

Hepatopancreaticobiliary disease

试验通俗题目

Impact of COVID-19 pandemic on Hepatobiliary and Pancreatic surgical services

试验专业题目

Impact of COVID-19 pandemic on Hepatobiliary and Pancreatic surgical services

申办单位信息
申请人联系人
申请人名称
联系人邮箱
联系人邮编

308433

联系人通讯地址
临床试验信息
试验目的

The hepato-pancreato-biliary (HPB) unit had to scale down the clinical workload and reallocate resources to combat COVID-19. We report local audit evaluating the impact of COVID-19 on the unit and its impact on cancer surgery.

试验分类
试验类型

连续入组

试验分期

回顾性研究

随机化

Retrospective study, no randomisation done

盲法

/

试验项目经费来源

NIL

试验范围

/

目标入组人数

200;347

实际入组人数

/

第一例入组时间

2019-01-01

试验终止时间

2020-06-30

是否属于一致性

/

入选标准

Methods We performed a comparative audit of the HPB team surgical workload for January-June 2019 (baseline) and 2020 (COVID-19). Elective and emergency cases performed under general anesthesia were audited. Elective cases included hernia surgeries, biliary surgeries (cholecystectomy and complex biliary resections), liver, and pancreatic resections. Emergency cases included cholecystectomies and laparotomies performed for general surgical indications.;

排除标准

We excluded endoscopy and procedures done under local anaesthesia.;

研究者信息
研究负责人姓名
试验机构

Nil

研究负责人电话
研究负责人邮箱
研究负责人邮编

308433

联系人通讯地址
<END>

Nil的其他临床试验

最新临床资讯

对摩熵医药数据库感兴趣,可以免费体验产品